Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083510 | 0.89 | TRPV1 (0.65) | SMN1; SMN2TRPV1NAMPTMEN1KMT2A | |
| SCHEMBL14083142 | 0.87 | KCNQ3 (0.62) | TRPV1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL14083313 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2NAMPTMEN1KMT2AKEAP1 | |
| SCHEMBL14084071 | 0.86 | TRPV1 (0.70) | TRPV1NAMPTMEN1KMT2AKEAP1 | |
| SCHEMBL14083120 | 0.85 | TRPV1 (0.59) | TRPV1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL14083124 | 0.85 | TRPV1 (0.72) | TRPV1NAMPTMEN1KMT2A | |
| SCHEMBL14083130 | 0.84 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL14083113 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2NAMPTMEN1KMT2AKEAP1 | |
| SCHEMBL14083392 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2NAMPTMEN1KMT2AKEAP1 | |
| SCHEMBL14083128 | 0.83 | TRPV1 (0.73) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | SMN1; SMN2 2099/4885TRPV1 1/4885NAMPT 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.